Clinical Trial Update: A Study to Learn About How Safe BAY 3389934 is, Its Suitable Dose, and How it Affects the Participants With Sepsis Induced Coagulopathy [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial assessing safety, dosing, and pharmacodynamic effects of BAY 3389934 in participants with sepsis-induced coagulopathy; recruitment is o…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sepsis
• Sepsis-induced Coagulopathy

Drugs mentioned

• BAY 3389934

Snippet

Sponsor: Bayer | Conditions: Sepsis, Coagulopathy | Phase 1 | Status: RECRUITING